NEW YORK, March 14 – Bioinformatics company Genomica said Wednesday it had appointed William Rich, CEO of Ciphergen Biosystems, to its board of directors, signaling the company’s growing interest in the field of proteomics.
"His experience in the industry in general and, in particular, the emerging field of protein-based biology research known as proteomics, will help us as we expand our product line and functionality," Teresa Ayers, CEO of Genomica, said in a statement.
Ciphergen of Fremont, Calif., was among the first companies to market protein chips to detect and validate proteins.
Ayers could not immediately be reached for comment regarding Genomica’s plans for the proteomics sector.
Genomica currently develops software that is designed to help researchers integrate and interpret genomics data culled from a variety of sources.
The company’s customers include AstraZeneca, GlaxoSmithKline and Aventis. Genomica of Boulder also has a deal to develop software that can be integrated with Applied Biosystems’ hardware.